COS2-4 COST-EFFECTIVE SCREENING FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COLONIZATION UPON HOSPITAL ADMISSION

Tuesday, January 7, 2014: 11:15 AM
Tanglin IV (The Regent Hotel)

Yan Sun, PhD1, Palvannan Kannapiran1, Kelvin Teo1, Bee Hoon Heng, MBBS2 and Brenda Ang, MBBS3, (1)National Healthcare Group, Singapore, Singapore, (2)National Healthcare group, Singapore, Singapore, (3)Tan Tock Seng Hospital, Singapore, Singapore, Singapore
Purpose: MRSA is one of the most common sources of nosocomial infections and it significantly contributes to poorer clinical outcomes and higher utilization.  Screening for MRSA colonization upon admission and isolation of identified MRSA carriers has been proposed as a strategy to prevent nosocomial spread of MRSA.  There are a few screening approaches available: universal screening vs. selective screening; rapid PCR screening vs. culture screening. The goal of this study is to identify the most cost effective screening strategy in Singapore context by comparing: rapid PCR screening for all; rapid PCR for selected high risk patients; culture screening for all; culture screening for selected high risk patients; no screening at all.

Method: All admitted patients to Tan Tock Seng Hospital in 2012 were included. A risk prediction model was developed and validated to select high risk patients for screening, using logistic regression and Bayesian Information Criteria. Markov decision analysis was applied to identify the most cost-effective screening strategy. The five strategies were compared in terms of the cost per infection prevented: PCR screening for all; PCR screening for selected high risk patients; no screening.  The modeling cycle (time length of transition) is 1 hour. The total modeled exposure time in hospital is about 120 hours (5 days). Costs to hospital will be used as the primary cost measure. We will also measure the cost from the perspectives of patients.

Result: In the risk stratification model, the important predictors identified were MRSA colonization history; elder age; infection or hospitalization in last 3 months; admitted from nursing homes; with kidney diseases, or stroke. The c-statistics of the ROC of the prediction model was 0.82 (95%CI: 0.81-0.83).  The MRSA prevalence at admission was about 7.3% in 2012.  Considering the cost of infection treatment, the incidence rate of hospital infection, the sensitivity and specificity of predicting the high risk patients, the most cost effective screening strategy was selective screening, which cost about $15.8K (95%CI: $7.8K - $ 21.9K) per infection prevented compared with no screening.

Conclusion: The study provides an evidence-based decision tool for policy makers to standardize care and set guidelines on cost effective infectious disease control in hospitals.